Thomas Powles on Muck Rack

Thomas Powles

As seen in: Color Research & Application, Nature, Wiley Online Library, MDPI, Taylor & Francis Online, The BMJ, JAMA (The Journal of the American Medical Association), JAMA Oncology, Medscape, The New England Journal of Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thomas

Contact Thomas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ASCO 2026: Enfortumab Vedotin + Pembrolizumab vs Chemotherapy for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 3.5 Year Follow-up and Response Analyses from the Phase 3 EV-302 Study

|
By Rashid K. Sayyid, Thomas Powles
| UroToday
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers oral abstract session. Dr. Thomas Powles presented 3.5-year follow-up data and response analyses from the phase 3 EV-302 study evaluating enfortumab vedotin + pembrolizumab (EV+P) for previously untreated locally advanced or metastatic urothelial carcinoma.
Open in Who Shared Issue with article?

KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma

|
By Sara Coca Membribes, Universitat de Barcelona, Thomas Powles
| European Urology
Brief ReportArticles in PressOpen access Affiliations & Notes aBarts Cancer Centre Biomedical Research Centre/CRUK ECMC, Queen Mary University of London, London, UK bDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA cVall d’Hebron University Hospital and Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, Spain dNottingham University Hospitals NHS Trust, Nottingham, UK eRoyal Marsden Hospital NHS Foundation Trust, London, UK fRoyal Marsden Hospital NHS...
Open in Who Shared Issue with article?

HERTHENA-PanTumor01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Advanced Solid Tumors

|
By Thomas Powles
| Texas Medical Center
10.1080/14796694.2025.2561539 Post-print Humans, Receptor, ErbB-3, Immunoconjugates, Antibodies, Monoclonal, Humanized, Neoplasms, Clinical Trials, Phase II as Topic, Female, Camptothecin, Male, Broadly Neutralizing Antibodies, Gastric cancer, melanoma, head and neck carcinoma, pancreatic cancer, prostate cancer, bladder cancer, esophageal cancer, gynecologic cancers, HER3, HER3-DXd, ADC yes Powles, Thomas; Bhatia, Aarti; Burtness, Barbara; et al., "HERTHENA-PanTumor01: A Phase II Study of...
Open in Who Shared Issue with article?
See all 149 licensed articles (244 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Thomas

Contact Thomas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified